AI assistant
Sending…
AIM ImmunoTech Inc. — Director's Dealing 2019
Jul 18, 2019
35334_dirs_2019-07-18_43f18e9a-544a-46ab-8292-406cade99424.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2019-07-16
Reporting Person: APPELROUTH STEWART (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-07-16 | Common Stock | J | 920 | $4.13 | Acquired | 28494 | Direct |
Footnotes
F1: Shares issued for 50 percent of Director's Fee for the first half of July, 2019.
More from AIM ImmunoTech Inc.
Share Issue/Capital Change
2026
Jun 11
Governance Information
2026
Jun 10
Capital/Financing Update
2026
Jun 10
Capital/Financing Update
2026
Jun 8
Report Publication Announcement
2026
Jun 4
Capital/Financing Update
2026
May 21
Capital/Financing Update
2026
May 21
Share Issue/Capital Change
2026
May 19
Capital/Financing Update
2026
May 19
Interim / Quarterly Report
2026
May 15